VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness
A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VSF-173 and Matching Placebo in Healthy Male and Female Subjects With Induced Excessive Sleepiness
Sponsor: Vanda Pharmaceuticals
Listed as NCT00467441, this PHASE2 trial focuses on Excessive Somnolence and remains completed. Sponsored by Vanda Pharmaceuticals, it has been updated 5 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Vanda Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .